Dr. Levin joins large Mid-Atlantic practice
R.D. Levin, MD, has joined Chesapeake Urology Associates and will see patients in the practice's Pine Heights Medical Center and Maple Lawn/Columbia offices in Maryland.
R.D. Levin, MD, has joined Chesapeake Urology Associates and will see patients in the practice’s Pine Heights Medical Center and Maple Lawn/Columbia offices in Maryland.
Dr. Levin treats all aspects of adult urology. His special interests are in urologic oncology, kidney stone conditions, prostate health, BPH, low testosterone, female incontinence, and reconstructive urology.
Dr. Levin began practicing urology in 1996. Prior to joining Chesapeake Urology Associates, he was in private practice in Florida, where he also served as a urologic oncologist at Aventura Hospital Cancer Center and Mount Sinai Comprehensive Cancer Center, both in Aventura. In addition, he was a member of the surgical review committee at Mount Sinai Hospital Medical Center and the Miami Heart Institute.
Dr. Levin completed his urologic residency at George Washington University School of Medicine in Washington and a fellowship in immunotherapy for urologic cancer at the National Cancer Institute, Bethesda, MD.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
